📈 Join us for LIVE TRADING action all day long in the 📈

 Market Master’s trading room

Join hundreds of us for LIVE TRADING action all day long in the Market Master’s trading room.

Talk about today’s focus stock, plus dozens of other breaking stocks that are moving during the day.



We have been on a rocky ride for the market over the last couple of weeks since I pointed out that we were finally entering a downtrend on the daily charts.

Things move very quickly in this market, so you need to be able to spot trends and react to them very quickly.  

I think we are going to see some bottom feeders come in this week, and the market will probably move higher… but don’t get too comfortable!

I am still finding incredible opportunities with momentum stocks right now.

Just like my last idea on Thursday, that rallied 25% the first day and then came back with another 30% during the following day.

If you look at pockets of the market where things are already heating up, you can avoid a lot of the pain and struggles of trying to trade large-cap tech stocks right now.

So, while the market has a little steam this morning, I think it is a great opportunity to get back to work and hunt for new ideas!

Right now, I want you to pull up Tiziana Life Sciences (TLSA) on your platform.

If you’re like me, the first thing you’ll notice is that it is hard not to type in “TSLA,” which is Tesla, of course.

We have all been hard-wired to do that over the years.

Since you probably did look at the car company first, you’ll notice that stock has lost about 20% over the last week.

TLSA (the correct stock) is the exact opposite right now.

This is an absolutely beautiful chart right now.

TLSA has managed to breakout 20% higher over the last week, which I thought was incredibly impressive considering that we just saw the largest stock market losses in a long time.

After a long base, the stock decided that as the market was dumping, it was finally time to wake up and start to move higher.

I have pointed out this weird type of move several times recently.  For some weird reason, I see a lot of stocks that traders have given up on making a move higher when the market moves lower.  

For whatever reason, you can pretty clearly see the “Gamma Trigger” move that signaled a few days ago with the double “GO” signals and a break back above the 20-hour moving average.

That move then led to a significant move to the upside.

It could be because the company has been issuing some fantastic news lately.

In fact, just this morning, you can read that they just announced tremendous results for patients in their clinical study.

With an oversold stock like this, it sure doesn’t take much positive news to get things turning in the right direction again.

I think this is an excellent idea to look at right now.

With all of the crazy volatility in the market, I prefer to avoid it and narrowly focus on short-term ideas that seem to be working.

As long as the trend stays above that 20-hour level I showed you in the chart above, I think this is a really good stock to consider right now.

It is hard to find any pockets of positive momentum right now, so I think TLSA is presenting us with a great opportunity today.

As a small biotech company, there is obviously a lot to digest about the business side of things as well.

Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biopharmaceutical company developing breakthrough therapies for neuroinflammatory and neurodegenerative diseases with high unmet needs.

Its lead candidate, Foralumab, is a monoclonal antibody therapy that reduces inflammation by targeting a protein on T cells called CD3.

One of TLSA’s key innovations is administering Foramulab intranasally, which produces minimal toxicity while creating local T cells that more easily cross the blood-brain barrier.

The upshot is that Foramulab may help suppress the activation of the brain’s most prominent immune cells — called “microglial cells” — which are overactive in diseases such as multiple sclerosis and Alzheimer’s. 

While there are other therapies that target CD3, Foralumab is the only CD3-targeting monoclonal antibody that is “fully human.” In theory, this should minimize adverse immune responses.

A similar anti-CD3 molecule that is only “humanized,” Teplizumab, was recently acquired by French pharma giant Sanofi for $2.9 billion.

Already, Foramulab has shown incredible promise in reducing microglial activation. 

Just this past week, TLSA presented data at the annual meeting of the American Academy of Neurology showing that nasal Foramulab “exhibited a reduction in microglial activation and disease stabilization in non-active secondary progressive multiple sclerosis [SPMS] patients … as observed through positron emission tomography (PET) imaging.”

Even more importantly, “clinically relevant improvements were observed in patient-reported outcomes, including stability … and improvements in fatigue levels.”

Dr. Tarun Singhal, an associate professor at Harvard Medical School, authored the study, noting that it “provides initial evidence that this fully human anti-CD3 has the potential to benefit this type of MS, which is the most difficult form to treat.”

Based on population prevalence data, TLSA estimates there are 94,000 SPMS patients in the US 155,000 in the EU.

But that form of multiple sclerosis isn’t the only potential indication for Foramulab. TLSA has also received Investigational New Drug clearance from the FDA for Foramulab as a treatment for Alzheimer’s, and it is also investigating the therapy for Long Covid, which is estimated to cost the US healthcare system almost $2.6 trillion.

TLSA’s pipeline

Dr. Howard Weiner, a professor of neurology at Harvard Medical School and the director and founder of the Partners Multiple Sclerosis Center notes that, “We have now seen the potential of intranasal foralumab to dampen microglial activation in three major neuroinflammatory-related diseases, which creates significant optionality for exploring its benefits in some of the most important and burdensome medical conditions of our time.”

Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky and nothing is ever guaranteed, so never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: While the stock market is likely to move higher over the next few days, it will be very volatile. I think it makes a lot of sense to focus on smaller stocks that have been bucking the downtrend and finding strength. TLSA fits the bill perfectly right now.

Make sure you keep TLSA on the top of your list today.

To Your Success,

Jeff Bishop

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!



*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.

*PAID ADVERTISEMENT. Raging Bull has currently been paid seventeen thousand five hundred dollars from Interactive Offers who was compensated by a third party not affiliated with the Company for advertising Tiziana Life Sciences Ltd. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Tiziana Life Sciences Ltd, increased trading volume, and possibly an increased share price of Tiziana Life Sciences Ltd’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Tiziana Life Sciences Ltd, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.